# CUPISCO: HCP commentary report

> 358 verified statements (37 from clinicians verified by NPI or staff page) from 62 commentary sources · 12 findings · updated Oct 31, 2026

## Report

- Trial: A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
- NCT ID: NCT03498521
- Registry: https://clinicaltrials.gov/study/NCT03498521
- Sponsor: Hoffmann-La Roche
- Phase: Phase 2
- Status: Completed
- Drugs tested: alectinib; vismodegib; ipatasertib
- Indication: unfavourable cancer of unknown primary
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: 50e8ebef0bdc27df9343580e21a5978ee70a473bf2ab71b4e86717d6896836c2

## Counts

- HCP commentary sources screened: 116
- Sources cited by verified statements: 68
- Verified statements: 358
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 37
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 32
- Voices cited: 29
- Cited voices identity-verified: 20
- Organisational or shared accounts (not counted as people): 10

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on CUPISCO in the sources reviewed for this edition leads to one open question: How should Medical Affairs communicate the value of early molecularly informed care while making endpoint uncertainty, treatment-specific evidence limits and feasible access explicit? Its leading findings: (1) A positive PFS result is not an established overall-survival benefit. (2) clinical magnitude and integrated-care value are different arguments. (3) the strategy result does not prove every treatment stratum or the atezolizumab add-on. 9 more findings follow. 116 sources screened, 68 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

How should Medical Affairs communicate the value of early molecularly informed care while making endpoint uncertainty, treatment-specific evidence limits and feasible access explicit?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A positive PFS result is not an established overall-survival benefit
- F2. Clinical magnitude and integrated-care value are different arguments
- F3. The strategy result does not prove every treatment stratum or the atezolizumab add-on
- F4. Population selection determines comparator validity and the place of local treatment
- F5. Early profiling is advocated alongside, not instead of, a sufficient diagnostic work-up
- F6. Tissue-of-origin treatment remains an explicitly contested alternative
- F7. Diagnostic rigor is viewed as both a major strength and a barrier to participation
- F8. Liquid biopsy addresses a real tissue constraint, with qualified feasibility and access
- F9. Testing, treatment access and referral must be considered together
- F10. Favorable tolerability language does not mean no harm or no monitoring burden
- F11. Patient experience gives the findings meaning without establishing cure
- F12. Molecularly informed classification is proposed, with integrated assessment and treatment-specific validation still needed

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 18 | 15 | 10 | 5 | recorded | 2 |
| F2 | 30 | 27 | 9 | 6 | recorded | 2 |
| F3 | 13 | 13 | 7 | 4 | recorded | 4 |
| F4 | 29 | 29 | 11 | 5 | recorded | 2 |
| F5 | 12 | 11 | 7 | 4 | recorded | 3 |
| F6 | 18 | 18 | 11 | 11 | recorded | 2 |
| F7 | 28 | 24 | 12 | 6 | recorded | 2 |
| F8 | 10 | 7 | 4 | 1 | none recorded | 2 |
| F9 | 13 | 9 | 9 | 6 | recorded | 3 |
| F10 | 7 | 5 | 5 | 1 | none recorded | 2 |
| F11 | 38 | 37 | 25 | 20 | recorded | 2 |
| F12 | 39 | 36 | 14 | 6 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 10 | 3 | 0 | 0 | 5 | 19 | 1 | 5 posts and articles, 4 podcasts and video, 1 publication | yes |
| F2 | 21 | 3 | 0 | 1 | 5 | 31 | 0 | 8 posts and articles, 1 podcast or video | yes |
| F3 | 5 | 5 | 0 | 1 | 2 | 14 | 0 | 3 posts and articles, 3 podcasts and video, 1 publication | yes |
| F4 | 9 | 1 | 2 | 1 | 16 | 31 | 0 | 1 post or article, 7 podcasts and video, 2 publications, 1 registry | yes |
| F5 | 6 | 1 | 2 | 0 | 3 | 15 | 0 | 1 post or article, 5 podcasts and video, 1 registry | yes |
| F6 | 8 | 3 | 1 | 3 | 3 | 19 | 1 | 7 posts and articles, 4 podcasts and video | yes |
| F7 | 12 | 2 | 3 | 4 | 7 | 32 | 0 | 5 posts and articles, 4 podcasts and video, 3 publications | yes |
| F8 | 3 | 0 | 5 | 0 | 2 | 13 | 0 | 3 podcasts and video, 1 registry | yes |
| F9 | 10 | 0 | 2 | 0 | 1 | 13 | 0 | 4 posts and articles, 5 podcasts and video | yes |
| F10 | 5 | 0 | 0 | 0 | 2 | 7 | 0 | 1 post or article, 2 podcasts and video, 2 publications | yes |
| F11 | 23 | 4 | 4 | 0 | 7 | 39 | 3 | 19 posts and articles, 6 podcasts and video | yes |
| F12 | 22 | 4 | 1 | 3 | 9 | 44 | 4 | 6 posts and articles, 5 podcasts and video, 3 publications | yes |

### Trial dimensions

- Primary endpoint: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1): F1 (6 shared claims), F2 (8 shared claims), F3 (3 shared claims), F4 (1 shared claims), F10 (1 shared claims), F11 (2 shared claims)
- Secondary endpoint: Overall Survival (OS): F1 (9 shared claims), F2 (1 shared claims), F10 (1 shared claims), F11 (4 shared claims), F12 (1 shared claims)
- Secondary endpoint: Objective Response Rate (ORR): no finding draws on it directly
- Secondary endpoint: Duration of Response (DOR): F3 (1 shared claims), F11 (3 shared claims)
- Secondary endpoint: Disease Control Rate (DCR): no finding draws on it directly
- Population and setting: F2 (2 shared claims), F4 (21 shared claims), F5 (1 shared claims), F6 (2 shared claims), F11 (3 shared claims), F12 (1 shared claims)
- The comparison: F2 (1 shared claims), F3 (8 shared claims), F4 (3 shared claims), F6 (2 shared claims), F12 (4 shared claims)
- Safety and tolerability: F10 (3 shared claims)
- Design and conduct: F2 (3 shared claims), F3 (1 shared claims), F4 (4 shared claims), F5 (1 shared claims), F7 (15 shared claims), F11 (1 shared claims), F12 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 358 | Paid |
| Trial aspects mapped | 16 | Free |
| Sources with links | 68 | Counts free |
| Speaker attribution for cited voices | 29 | Paid |

## Trial aspects

15 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) | discussed | 28 | 20 |
| Secondary endpoint: Overall Survival (OS) | discussed | 16 | 13 |
| Secondary endpoint: Objective Response Rate (ORR) | discussed | 2 | 2 |
| Secondary endpoint: Duration of Response (DOR) | discussed | 3 | 2 |
| Secondary endpoint: Disease Control Rate (DCR) | no commentary found | 0 | 0 |
| Population and setting | discussed | 31 | 13 |
| The comparison | discussed | 33 | 15 |
| Safety and tolerability | discussed | 3 | 3 |
| Design and conduct | discussed | 35 | 17 |
| Timing of profiling and limits of the primary-tumor search | discussed | 23 | 10 |
| Origin inference, alternative treatment selection and diagnostic harm | discussed | 18 | 11 |
| Tissue stewardship and liquid-biopsy feasibility | discussed | 9 | 3 |
| Treatment access, guideline adoption and referral | discussed | 21 | 13 |
| Patient experience, durable-remission anecdotes and noncurative expectations | discussed | 33 | 23 |
| Molecular heterogeneity, proposed classification and next research priorities | discussed | 30 | 11 |
| Integrated-care value, benefit magnitude and resource allocation | discussed | 31 | 8 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 98 | 46 |
| YouTube | 12 | 12 |
| Bluesky threads | 3 | 1 |
| Podcasts | 2 | 2 |
| LinkedIn posts | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 5 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2018-10-19 to 2026-09-18
- Cited window: 2018-10-19 to 2026-09-18
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
- Registry: NCT03498521 (https://clinicaltrials.gov/study/NCT03498521)
- Study IDs: MX39795 · 2017-003040-20
- Sponsor: Hoffmann-La Roche
- Collaborators: Foundation Medicine
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Completed
- Enrollment: 529 (actual)
- Start: 2018-07-10 (actual)
- Primary completion: 2023-02-14 (actual)
- Primary endpoint: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) (From randomization to the first occurrence of disease progression or death from any cause, until 330 PFS events were observed (approx. 4.3 years for MGT Cat 1 and 3.4 years for Chemotherapy Cat 1).)
- Intervention: Alectinib (drug)
- Intervention: Vismodegib (drug)
- Intervention: Ipatasertib (drug)
- Intervention: Olaparib (drug)
- Intervention: Erlotinib (drug)
- Intervention: Bevacizumab (drug)
- Intervention: Vemurafenib (drug)
- Intervention: Cobimetinib (drug)
- Intervention: Trastuzumab Subcutaneous (SC) (drug)
- Intervention: Pertuzumab (drug)
- Intervention: Atezolizumab (drug)
- Intervention: Carboplatin (drug)
- Intervention: Paclitaxel (drug)
- Intervention: Cisplatin (drug)
- Intervention: Gemcitabine (drug)
- Intervention: Entrectinib (drug)
- Intervention: Ivosidenib (drug)
- Intervention: Pemigatinib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about treatment selection for cancer of unknown primary.
- Not yet captured in this edition: a view on genomic profiling–guided treatment versus platinum chemotherapy in cancer of unknown primary.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 92 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative sample of all HCP opinion. Reposts, shared presentation accounts and repeated statements do not establish independent agreement.
- Coverage of connected alternative-study discussions remains incomplete in this edition, including CUP-ONE's diagnostic comparison, separate molecular-strategy studies' survival and reclassification findings, and further research uses of GEFCAPI04 data and tissue. Those questions should not be treated as resolved by this report.
- Several podcast and video passages cannot be assigned to a named speaker. Their views remain attributed to the episode or discussion and are not treated as additional distinct clinicians.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Sources describe some contributors as involved in, presenting or reporting CUPISCO. Those descriptions are attributed source context, not independently established trial roles or evidence of external confirmation.
- The material spans recruitment-period expectations, initial-results reactions and updated analyses. Post dates do not establish presentation dates, and differences across sources do not establish that a speaker changed their mind.
- Some oral accounts use unspecified survival terminology or numbers that differ from publications. They are preserved as statements made rather than silently converted into corrected trial results.
- Long remissions, individual survival experiences, retrospective treatment matching and exploratory molecular clusters do not establish comparative efficacy for an individual drug or patient.
- Access and reimbursement accounts are local, dated and sometimes explicitly experiential or unverified. A comprehensive current regulatory assessment was not available.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (358 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (20 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/cupisco-nct03498521
- Agents: POST https://www.erudio.com/api/orders with {"report": "cupisco-nct03498521", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=cupisco-03498521

## Cite

Erudio Health. CUPISCO (NCT03498521): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/cupisco-nct03498521

## Machine access

- JSON: https://www.erudio.com/reports/cupisco-nct03498521.json
- Markdown: https://www.erudio.com/reports/cupisco-nct03498521.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "cupisco-03498521"}`